VIVIMEDLAB — Vivimed Labs Balance Sheet
0.000.00%
- IN₹504.95m
- IN₹4.40bn
- IN₹699.89m
Annual balance sheet for Vivimed Labs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Preliminary |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 71.8 | 37.6 | 722 | 492 | 77.2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,868 | 1,729 | 1,968 | 1,312 | 841 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,073 | 3,323 | 3,426 | 3,276 | 1,680 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4,026 | 2,988 | 2,835 | 2,715 | 2,548 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 12,660 | 9,883 | 9,509 | 9,208 | 7,535 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3,734 | 4,243 | 4,103 | 4,082 | 4,481 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 9,017 | 9,489 | 9,564 | 9,560 | 9,640 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 3,643 | 394 | -54.6 | -352 | -2,106 |
| Total Liabilities & Shareholders' Equity | 12,660 | 9,883 | 9,509 | 9,208 | 7,535 |
| Total Common Shares Outstanding |